U.S. markets close in 1 hour 49 minutes

Globe Life Inc. (GL-PC)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
25.83-0.06 (-0.23%)
As of 1:59PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close25.89
Bid25.77 x 900
Ask25.85 x 1200
Day's Range25.70 - 25.87
52 Week Range25.70 - 25.87
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)1.14
PE Ratio (TTM)3.78
EPS (TTM)6.83
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Globe Life Inc. Announces First Quarter 2021 Earnings Release And Conference Call
    PR Newswire

    Globe Life Inc. Announces First Quarter 2021 Earnings Release And Conference Call

    Globe Life Inc. (NYSE: GL) will release First Quarter 2021 earnings after the market closes on Wednesday, April 21, 2021. At that time a copy of the Company's Q1 - 2021 earnings press release and any other financial and statistical information about the quarter will be available on the Company's website at https://investors.globelifeinsurance.com/ under Financial Reports and Other Financial Information. In conjunction with the First Quarter 2021 Earnings Release of Globe Life Inc. you are invited to listen to a conference call that will be broadcast live over the Internet on Thursday, April 22, 2021 at 11:00 am Eastern (10:00 am Central).

  • Introducing Globe Life (NYSE:GL), A Stock That Climbed 85% In The Last Five Years
    Simply Wall St.

    Introducing Globe Life (NYSE:GL), A Stock That Climbed 85% In The Last Five Years

    The main point of investing for the long term is to make money. But more than that, you probably want to see it rise...

  • Globe Life Ramps Up Quarterly Dividend By 5.3%

    Globe Life Ramps Up Quarterly Dividend By 5.3%

    Globe Life Inc. increased its quarterly cash dividend by 5.3% to $0.1975 per share. Prior to this, the life insurance company raised its dividend payout by 9% to $0.1875 in March 2020. Globe Life (GL) announced that the new dividend will be paid on April 30 to shareholders of record as of April 5. The company’s annual dividend of $0.79 per share now reflects a dividend yield of 0.8%. Last month, Globe Life reported 4Q results. The company’s 4Q earnings rose 2% year-over-year to $1.74 per share and outpaced Street estimates of $1.72. Revenues came in at $1.23 billion, up 7.9% and topped analysts’ expectations of $1.2 billion. Life premiums increased 10% at the American Income Life division, while advanced 7% at the Direct to Consumer division. (See Globe Life stock analysis on TipRanks) On Feb. 25, Morgan Stanley analyst Nigel Dally increased the stock’s price target to $95 (3.5% downside potential) from $93 and maintained a Sell rating. The rest of the Street is sidelined on the stock with a Hold consensus rating based on 1 Buy, 1 Hold, and 1 Sell. The average analyst price target of $93.67 implies around 4.9% downside potential to current levels. Shares have increased 24.6% over the last six months. Related News: Catalyst Pharma To Buy Back $40M In Stock; Shares Gain Pre-Market AutoZone To Buy Back $1.5B In Stock Saratoga Investment Bumps Up Quarterly Dividend More recent articles from Smarter Analyst: RLX Technology’s 4Q Profit Exceeds Analysts’ Expectations, Revenue Rises MSG Entertainment Inks Deal To Buy MSG Networks; Shares Tank 10% Magnachip To Be Acquired By Wise Road Capital For $1.4B; Shares Pop 27% Aspira Inks Agreement For Ovarian Cancer Test; Shares Rise 32% Post-Market